Analysis of COVID-19 patient outcomes with molnupiravir treatment and the role of risk factors: a single-centre retrospective descriptive study.

IF 1.1 4区医学 Q4 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Central European journal of public health Pub Date : 2024-12-01 DOI:10.21101/cejph.a8398

Ondrej Zahornacký, Štefan Porubčin, Alena Rovňáková, Pavol Jarčuška, Dária Semenovová, Paulína Kubalcová, Erik Dorko, Kvetoslava Rimárová

{"title":"Analysis of COVID-19 patient outcomes with molnupiravir treatment and the role of risk factors: a single-centre retrospective descriptive study.","authors":"Ondrej Zahornacký, Štefan Porubčin, Alena Rovňáková, Pavol Jarčuška, Dária Semenovová, Paulína Kubalcová, Erik Dorko, Kvetoslava Rimárová","doi":"10.21101/cejph.a8398","DOIUrl":null,"url":null,"abstract":"Objective: This study aims to describe the outcomes of COVID-19 patients treated with molnupiravir and to explore the associations with various risk factors.Methods: We conducted a single-centre, descriptive, retrospective study without a comparison group.Results: Out of 141 patients, 70 (49.7%) required follow-up outpatient care. In the subgroup of 66 (46.8%) hospitalized patients, 28 (19.9%) developed interstitial viral pneumonia, with 6 (4.3%) deaths. Unvaccinated patients had a higher incidence of pneumonia (p = 0.020), and obesity was a significant risk factor for both pneumonia (p = 0.001) and mortality (p = 0.011). Patients over 60 years (p = 0.040) and those with cardiovascular diseases (p = 0.026) also had increased pneumonia risk. Male sex was associated with a higher risk of death (p = 0.020).Conclusion: Molnupiravir treatment was linked to reduced risks of hospitalization and death, particularly in high-risk patients. Vaccination provided additional protection, and obesity obstructive pulmonary disease and autoimmune diseases were significant risk factors for severe outcomes.","PeriodicalId":9823,"journal":{"name":"Central European journal of public health","volume":"32 Supplement","pages":"104-110"},"PeriodicalIF":1.1000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Central European journal of public health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21101/cejph.a8398","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study aims to describe the outcomes of COVID-19 patients treated with molnupiravir and to explore the associations with various risk factors.

Methods: We conducted a single-centre, descriptive, retrospective study without a comparison group.

Results: Out of 141 patients, 70 (49.7%) required follow-up outpatient care. In the subgroup of 66 (46.8%) hospitalized patients, 28 (19.9%) developed interstitial viral pneumonia, with 6 (4.3%) deaths. Unvaccinated patients had a higher incidence of pneumonia (p = 0.020), and obesity was a significant risk factor for both pneumonia (p = 0.001) and mortality (p = 0.011). Patients over 60 years (p = 0.040) and those with cardiovascular diseases (p = 0.026) also had increased pneumonia risk. Male sex was associated with a higher risk of death (p = 0.020).

Conclusion: Molnupiravir treatment was linked to reduced risks of hospitalization and death, particularly in high-risk patients. Vaccination provided additional protection, and obesity obstructive pulmonary disease and autoimmune diseases were significant risk factors for severe outcomes.

查看原文本刊更多论文

莫诺匹拉韦治疗的COVID-19患者结局分析及危险因素的作用：一项单中心回顾性描述性研究

目的：本研究旨在描述新型冠状病毒肺炎（COVID-19）患者使用莫那匹拉韦治疗的疗效，并探讨其与各种危险因素的相关性。方法：我们进行了一项无对照组的单中心、描述性、回顾性研究。结果：141例患者中，70例（49.7%）需要门诊随访。在66例住院患者（46.8%）中，28例（19.9%）发生间质性病毒性肺炎，6例（4.3%）死亡。未接种疫苗的患者肺炎发病率较高（p = 0.020），肥胖是肺炎（p = 0.001）和死亡率（p = 0.011）的重要危险因素。60岁以上患者（p = 0.040）和心血管疾病患者（p = 0.026）肺炎风险也增加。男性与较高的死亡风险相关（p = 0.020）。结论：Molnupiravir治疗可降低住院和死亡风险，特别是在高危患者中。疫苗接种提供了额外的保护，肥胖、阻塞性肺疾病和自身免疫性疾病是严重后果的重要危险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Central European journal of public health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-

CiteScore

1.90

自引率

0.00%

发文量

期刊介绍： The Journal publishes original articles on disease prevention and health protection, environmental impacts on health, the role of nutrition in health promotion, results of population health studies and critiques of specific health issues including intervention measures such as vaccination and its effectiveness. The review articles are targeted at providing up-to-date information in the sphere of public health. The Journal is geographically targeted at the European region but will accept specialised articles from foreign sources that contribute to public health issues also applicable to the European cultural milieu.